Blay JY, Kang YK, Nishida T, von Mehren M (2021) Gastrointestinal stromal tumours. Nat Rev Dis Primers 7:22

Article  PubMed  Google Scholar 

Bouchet S, Poulette S, Titier K, Moore N, Lassalle R, Abouelfath A, Italiano A, Chevreau C, Bompas E, Collard O, Duffaud F, Rios M, Cupissol D, Adenis A, Ray-Coquard I, Bouche O, Le Cesne A, Bui B, Blay JY, Molimard M (2016) Relationship between Imatinib trough concentration and outcomes in the treatment of advanced Gastrointestinal stromal tumours in a real-life setting. Eur J Cancer 57:31–38

Article  CAS  PubMed  Google Scholar 

Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, Antonescu CR, Allis CD, Sawyers CL (2010) ETV1 is a lineage survival factor that cooperates with KIT in Gastrointestinal stromal tumours. Nature 467:849–U117

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cohen R, Greenberg E, Nemlich Y, Schachter J, Markel G (2015) miR-17 regulates melanoma cell motility by inhibiting the translation of ETV1. Oncotarget 6:19006–19016

Article  PubMed  PubMed Central  Google Scholar 

Dalle FC, Gagno S, Roncato R, Polesel J, Zanchetta M, Buzzo M, Posocco B, De Mattia E, Borsatti R, Puglisi F, Foltran L, Guardascione M, Buonadonna A, Cecchin E, Toffoli G (2023) CYP2D6 and CYP2C8 pharmacogenetics and Pharmacological interactions to predict Imatinib plasmatic exposure in GIST patients. Br J Clin Pharmacol 89:1089–1098

Article  Google Scholar 

Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, Joensuu H, von Mehren M (2009) Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic Gastrointestinal stromal tumors. J Clin Oncol 27:3141–3147

Article  CAS  PubMed  Google Scholar 

Dermawan JK, Rubin BP (2022) Molecular pathogenesis of Gastrointestinal stromal tumor: A paradigm for personalized medicine. Annu Rev Pathol 17:323–344

Article  CAS  PubMed  Google Scholar 

Dermawan JK, Kelly C, Gao Z, Smith S, Jadeja B, Singer S, Tap WD, Chi P, Antonescu CR (2023) Novel genomic risk stratification model for primary Gastrointestinal stromal tumors (GIST) in the adjuvant therapy era. Clin Cancer Res 29:3974–3985

Article  CAS  PubMed  PubMed Central  Google Scholar 

Di Vito A, Ravegnini G, Gorini F, Aasen T, Serrano C, Benuzzi E, Coschina E, Monesmith S, Morroni F, Angelini S, Hrelia P (2023) The multifaceted landscape behind Imatinib resistance in Gastrointestinal stromal tumors (GISTs): A lesson from ripretinib. Pharmacol Ther 248:108475

Article  PubMed  Google Scholar 

Gao G, Xiu D, Yang B, Sun D, Wei X, Ding Y, Ma Y, Wang Z (2019) miR-129-5p inhibits prostate cancer proliferation via targeting ETV1. Onco Targets Ther 12:3531–3544

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao Z, Li C, Sun H, Bian Y, Cui Z, Wang N, Wang Z, Yang Y, Liu Z, He Z, Li B, Li F, Li Z, Wang L, Zhang D, Yang L, Xu Z, Li X, Xu H (2023) N(6)-methyladenosine-modified USP13 induces pro-survival autophagy and Imatinib resistance via regulating the stabilization of autophagy-related protein 5 in Gastrointestinal stromal tumors. Cell Death Differ 30:544–559

Article  CAS  PubMed  Google Scholar 

Ge Y, Bai H, Mazzocca A, Zhang J, Wang Z, Wu X (2024) Contribution of genetic polymorphism in ABCB1 to individual variations of Imatinib plasma levels in patients with Gastrointestinal stromal tumor. J Gastrointest Oncol 15:577–584

Article  PubMed  PubMed Central  Google Scholar 

Ghorbani M, Namazi S, Dehghani M, Razi F, Khalvati B, Dehshahri A (2024) Gene polymorphisms of TACR1 serve as the potential Pharmacogenetic predictors of response to the neurokinin-1 receptor antagonist-based antiemetic regimens: a candidate-gene association study in breast cancer patients. Cancer Chemother Pharmacol 94:237–250

Article  CAS  PubMed  Google Scholar 

Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, Roden DM, Schaefer CA, Shuldiner AR, Skaar T, Tantisira K, Tyndale RF, Wang L, Weinshilboum RM, Weiss ST, Zineh I (2007) The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 81:328–345

Article  CAS  PubMed  Google Scholar 

Hayashi Y, Bardsley MR, Toyomasu Y, Milosavljevic S, Gajdos GB, Choi KM, Reid-Lombardo KM, Kendrick ML, Bingener-Casey J, Tang CM, Sicklick JK, Gibbons SJ, Farrugia G, Taguchi T, Gupta A, Rubin BP, Fletcher JA, Ramachandran A, Ordog T (2015) Platelet-Derived Growth Factor Receptor-alpha Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1. Gastroenterology 149:420–32.e16

Article  CAS  PubMed  Google Scholar 

Incorvaia L, De Biase D, Nannini M, Fumagalli E, Vincenzi B, De Luca I, Brando C, Perez A, Pantaleo MA, Gasperoni S, D’Ambrosio L, Grignani G, Maloberti T, Pedone E, Bazan RT, Mazzocca A, Algeri L, Dimino A, Barraco N, Serino R, Gristina V, Galvano A, Bazan V, Russo A, Badalamenti G (2024) KIT/PDGFRA variant allele frequency as prognostic factor in Gastrointestinal stromal tumors (GISTs): results from a Multi-Institutional cohort study. Oncologist 29:e141–e151

Article  PubMed  Google Scholar 

Jia N, Tong H, Zhang Y, Katayama H, Wang Y, Lu W, Zhang S, Wang J (2019) CeRNA expression profiling identifies KIT-Related circRNA-miRNA-mRNA networks in Gastrointestinal stromal tumour. Front Genet 10:825

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khosroyani HM, Klug LR, Heinrich MC (2023) TKI treatment sequencing in advanced Gastrointestinal stromal tumors. Drugs 83:55–73

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kloth J, Verboom MC, Swen JJ, van der Straaten T, Sleijfer S, Reyners A, Steeghs N, Gelderblom H, Guchelaar HJ, Mathijssen R (2018) Genetic polymorphisms as predictive biomarker of survival in patients with Gastrointestinal stromal tumors treated with Sunitinib. Pharmacogenomics J 18:49–55

Article  CAS  PubMed  Google Scholar 

Li J, Shen L (2020) The current status of and prospects in research regarding Gastrointestinal stromal tumors in China. Cancer 126 Suppl 9:2048–2053

Article  Google Scholar 

Li J, Lai Y, Ma J, Liu Y, Bi J, Zhang L, Chen L, Yao C, Lv W, Chang G, Wang S, Ouyang M, Wang W (2017) miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer. BMC Cancer 17(1):745

Liu J, Chen Z, Chen H, Hou Y, Lu W, He J, Tong H, Zhou Y, Cai W (2017) Genetic polymorphisms contribute to the individual variations of Imatinib mesylate plasma levels and adverse reactions in Chinese GIST patients. Int J Mol Sci 18(3):603

Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della CK, Wisner L, Iorio M, Shakalya K, Garewal H, Nagle R, Bearss D (2007) A novel tyrosine kinase switch is a mechanism of Imatinib resistance in Gastrointestinal stromal tumors. Oncogene 26:3909–3919

Article  CAS  PubMed  Google Scholar 

Miettinen M, Sarlomo-Rikala M, Lasota J (1999) Gastrointestinal stromal tumors: recent advances in Understanding of their biology. Hum Pathol 30:1213–1220

Article  CAS  PubMed  Google Scholar 

Ni B, Li Q, Zhuang C, Huang P, Xia X, Yang L, Ma X, Huang C, Zhao W, Tu L, Shen Y, Zhu C, Zhang Z, Zhao E, Wang M, Cao H (2022) The nerve-tumour regulatory axis GDNF-GFRA1 promotes tumour dormancy, Imatinib resistance and local recurrence of Gastrointestinal stromal tumours by achieving autophagic flux. Cancer Lett 535:215639

Article  CAS  PubMed  Google Scholar 

Ou WB, Ni N, Zuo R, Zhuang W, Zhu M, Kyriazoglou A, Wu D, Eilers G, Demetri GD, Qiu H, Li B, Marino-Enriquez A, Fletcher JA (2019) Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence. Oncogene

Ouyang M, Wang H, Ma J, Lü W, Li J, Yao C, Chang G, Bi J, Wang S, Wang W (2015) COP1, the negative regulator of ETV1, influences prognosis in triple-negative breast cancer. BMC Cancer 15:132

Proano-Perez E, Serrano-Candelas E, Mancia C, Navines-Ferrer A, Guerrero M, Martin M (2022) SH3BP2 Silencing increases MiRNAs targeting ETV1 and Microphthalmia-Associated transcription factor, decreasing the proliferation of Gastrointestinal stromal tumors. Cancers (Basel) 14(24):6198

Ran L, Sirota I, Cao Z, Murphy D, Chen Y, Shukla S, Xie Y, Kaufmann MC, Gao D, Zhu S, Rossi F, Wongvipat J, Taguchi T, Tap WD, Mellinghoff IK, Besmer P, Antonescu CR, Chen Y, Chi P (2015) Combined Inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. Cancer Discov 5:304–315

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raut CP, Espat NJ, Maki RG, Araujo DM, Trent J, Williams TF, Purkayastha DD, DeMatteo RP (2018) Efficacy and tolerability of 5-Year adjuvant Imatinib treatment for patients with resected Intermediate- or High-Risk primary Gastrointestinal stromal tumor: the PERSIST-5 clinical trial. JAMA Oncol 4:e184060

Article  PubMed  PubMed Central  Google Scholar 

Ravegnini G, Serrano C, Simeon V, Sammarini G, Nannini M, Roversi E, Urbini M, Ferre F, Ricci R, Tarantino G, Pantaleo MA, Hrelia P, Angelini S (2019) The rs17084733 variant in the KIT 3’ UTR disrupts a miR-221/222 binding site in Gastrointestinal stromal tumour: a sponge-like mechanism conferring disease susceptibility. Epigenetics 14:545–557

Article  PubMed  PubMed Central  Google Scholar 

Salzman DW, Weidhaas JB (2013) SNPing cancer in the bud: MicroRNA and MicroRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer. Pharmacol Ther 137:55–63

Article